Clinical Trial Update: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations [Phase 3]

View source ↗

Summary

An ongoing Phase 3 clinical trial comparing datopotamab deruxtecan plus pembrolizumab versus pembrolizumab alone as first-line treatment for advanced or metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dato-DXd (datopotamab deruxtecan)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Metastatic Non Small Cell Lung Cancer | Phase 3 | Status: RECRUITING